LV14273B - Novel salts of acetylsalicylic acid - Google Patents

Novel salts of acetylsalicylic acid Download PDF

Info

Publication number
LV14273B
LV14273B LVP-09-117A LV090117A LV14273B LV 14273 B LV14273 B LV 14273B LV 090117 A LV090117 A LV 090117A LV 14273 B LV14273 B LV 14273B
Authority
LV
Latvia
Prior art keywords
acetylsalicylic acid
acid
addition salt
acetylsalicylate
salts
Prior art date
Application number
LVP-09-117A
Other languages
Latvian (lv)
Other versions
LV14273A (en
Inventor
Ivars KALVIŅŠ
Anatolijs Birmans
Māris VĒVERIS
Antons ĻEBEDEVS
Anatolijs MIŠŅOVS
Original Assignee
Tetra, Sia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tetra, Sia filed Critical Tetra, Sia
Priority to LVP-09-117A priority Critical patent/LV14273B/en
Priority to KR1020127001929A priority patent/KR20120050437A/en
Priority to CA2766048A priority patent/CA2766048A1/en
Priority to NZ597510A priority patent/NZ597510A/en
Priority to EP10735094.4A priority patent/EP2445861B1/en
Priority to US13/377,926 priority patent/US8889902B2/en
Priority to UAA201200601A priority patent/UA106379C2/en
Priority to JP2012517421A priority patent/JP5706409B2/en
Priority to BRPI1009600A priority patent/BRPI1009600A2/pt
Priority to EA201200038A priority patent/EA021588B1/en
Priority to PCT/LV2010/000007 priority patent/WO2010151095A1/en
Priority to CN201080028833.9A priority patent/CN102803199B/en
Priority to GEAP201012546A priority patent/GEP20146015B/en
Publication of LV14273A publication Critical patent/LV14273A/en
Publication of LV14273B publication Critical patent/LV14273B/en
Priority to IL217036A priority patent/IL217036A/en
Priority to ZA2012/00592A priority patent/ZA201200592B/en
Priority to HK12110406.3A priority patent/HK1169648A1/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Novel betaine salts of acetylsalicylic acid, namely 4-trimethylammoniobutanoate acetylsalicylate (meldonium acetylsalicylate), Z-carnitine acetylsalicylate and 3-(trimethylammonioamino)-propanoate (meldonium) acetylsalicylate. Use of meldonium acetylsalicylate as antiplatelet agent for treating various pathologies induced by platelet aggregation, anti-inflammatory and antihyperlipidemic agent.

Description

IZGUDROJUMA NOZARE UN TEHNIKAS LĪMENISFIELD OF THE INVENTION AND TECHNICAL FIELD

Aprakstītais izgudrojums kopumā attiecas uz acetilsalicilskābes sāļiem, īpaši uz jauniem un ūdenī šķīstošiem acetilsalicilskābes sāļiem un to iegūšanas paņēmienu. Acetilsalicilskābe ir ļoti plaši lietotas zāles, kas pazīstama galvenokārt ar tās pretsāpju īpašībām. Tās pielietošanas diapazonu lielā mērā ierobežo zemā šķīdība ūdenī (aptuveni 0,3%). Bez Li, Na, Mg un Ca sāļiem ir aprakstīti ari vairāki sāļi ar bāziskām aminoskābēm [US 4, 265,888], Katram no šiem sāļiem ir zināmas priekšrocības un trūkumi, tāpēc ir vēlama jaunu acetilsalicilskābes sāļu iegūšana ar potenciāli vēl labākām īpašībām.The present invention relates generally to the salts of acetylsalicylic acid, in particular to the novel and water-soluble salts of acetylsalicylic acid and the process for their preparation. Acetylsalicylic acid is a very widely used drug known mainly for its analgesic properties. Its application range is largely limited by its low water solubility (about 0.3%). In addition to the Li, Na, Mg and Ca salts, several salts with basic amino acids have been described [US 4, 265,888]. Each of these salts has certain advantages and disadvantages, so it is desirable to obtain new acetylsalicylic acid salts with potentially even better properties.

IZGUDROJUMA KOPSAVILKUMSSUMMARY OF THE INVENTION

Šī izgudrojuma būtība ir jauna tipa acetilsalicilskābes sāļu atrašana ar zināmiem betaīna tipa savienojumiem. Negaidīti un pārsteidzoši mēs atradām, ka acetilsalicilskābe veido stabilus, ūdenī šķīstošus, kristāliskus sāļus ar zināmiem betaīniem, kas paši ir higroskopiskas vielas.The essence of this invention is the discovery of a novel type of acetylsalicylic acid salts with known betaine-type compounds. Unexpectedly and surprisingly, we have found that acetylsalicylic acid forms stable, water-soluble, crystalline salts with known betaines, which are themselves hygroscopic.

Tātad šī izgudrojuma mērķis ir iegūt acetilsalicilskābes sāļus, kas labi šķīst ūdenī, bet tajā pašā laikā ir ļoti stabili un ilgi uzglabājami.Thus, it is an object of the present invention to obtain acetylsalicylic acid salts which are highly water soluble but at the same time very stable and long storage.

Šī izgudrojuma papildu mērķis ir piedāvāt šādu sāļu iegūšanas paņēmienu.It is a further object of the present invention to provide a process for the preparation of such salts.

Tā kā betaīna tipa savienojumiem, kas ir iekļauti jaunajos acetilsalicilskābes sāļos, pašiem piemīt dažādas farmakoloģiskās aktivitātes, jaunaiem acetilsalicilskābes sāļiem var būt papildu labvēlīgas aktivitātes tām, kas piemīt acetilsalicilskābei vai betaīniem, tostarp jaunas farmakoloģiskas aktivitātes.Because betaine-like compounds included in the new acetylsalicylic acid salts themselves have different pharmacological activities, new acetylsalicylic acid salts may have additional beneficial activities to those of the acetylsalicylic acid or betaines, including new pharmacological activities.

IETEICAMIE IZGUDROJUMA REALIZĀCIJAS VARIANTIRECOMMENDED EMBODIMENTS OF THE INVENTION

Turpmāki aprakstīti piedāvātā izgudrojuma dažādu sāļu un paņēmienu piemēri.The following describes examples of various salts and methods of the present invention.

1. piemērs. 4-trimetilamoniobutanoāta acetilsalicilskābes aditīvais sāls γ-Butirobetaīna dihidrātu (1,81 g, 10 mmol) un acetilsalicilskābi (1,80 g, mmol) izšķīdina etanolā (20 ml). Šķīdumu koncentrē vakuumā pie aptuveni 40 °C līdz sīrupa konsistencei, kas atdziestot kristalizējas. Kristālisko masu saberž ar acetonu (50 ml), nofiltrē, noskalo ar acetonu un žāvē vakuumā istabas temperatūrā. Bezkrāsainu kristālu ar k.t. 120-122 °C iznākums ir 3,04 g (93,5%). Viela ir ūdenī šķīstoša, stabila parastos apstākļos.Example 1: The acetylsalicylic acid addition salt of 4-trimethylammoniobutanoate γ-Butyrobetaine dihydrate (1.81 g, 10 mmol) and acetyl salicylic acid (1.80 g, mmol) are dissolved in ethanol (20 mL). The solution is concentrated in vacuo at about 40 ° C to a syrupy consistency which crystallizes upon cooling. The crystalline mass is triturated with acetone (50 mL), filtered, rinsed with acetone and vacuum dried at room temperature. Colorless crystals with k.t. 120-122 ° C, yield 3.04 g (93.5%). The substance is water soluble, stable under normal conditions.

’H-KMR spektrs (CDC13, 200 MHz, δ): 1,93-2,12 (2H, m, CH?CH?CH?); 2,33 (3H, s, COCH3); 2,40 (2H, t, J = 7,0 Hz, CH2COO~); 3,09 (9H, s, Me3N); 3,24-3,37 (2H, m, CH2N); 7,16 (1H, dd, J = 1,1 un 8,1 Hz, H-3); 7,38 (1H, ddd, J = 1,1, 7,6 un 7,6 Hz, H-5); 7,56 (1H, ddd, J = 1,8, 7,6 un 8,1 Hz, H-4); 7,79 m.d. (1H, dd, J = 1,8 un 7,6 Hz, H-6).1 H-NMR Spectrum (CDCl 3 , 200 MHz, δ): 1.93-2.12 (2H, m, CH? CH? CH?); 2.33 (3H, s, COCH 3 ); 2.40 (2H, t, J = 7.0 Hz, CH 2 COO -); 3.09 (9H, s, Me 3 N); 3.24-3.37 (2H, m, CH 2 N); 7.16 (1H, dd, J = 1.1 and 8.1 Hz, H-3); 7.38 (1H, ddd, J = 1.1, 7.6 and 7.6 Hz, H-5); 7.56 (1H, ddd, J = 1.8, 7.6 and 8.1 Hz, H-4); 7.79 md (1H, dd, J = 1.8 and 7.6 Hz, H-6).

Ci6H23NO6. Aprēķināts, %: C 59,07; H 7,13; N 4,30.Ci 6 H2 3 NO 6 . Calculated,%: C, 59.07; H, 7.13; N, 4.30.

Atrasts, %: C 59,17; H 7,20; N 4,23.Found,%: C, 59.17; H, 7.20; N, 4.23.

Jauno sali raksturo pulvera rentgenogramma (Cu Ka- radiacija) ar maksimumiem pie šādām 2Θ vērtībām: 5,10; 13,58, 13,83; 15,02; 15,17; 17,89; 19,33; 19,87; 21,85; 22,05; 23,32; 23,56; 23,92; 24,75; 25,55; 25,80; 27,05; 27,91; 30,25 ± 0,2°.The new island is characterized by a powder X-ray (Cu K a - radiation) with peaks at the following 2Θ values: 5.10; 13.58, 13.83; 15.02; 15.17; 17.89; 19.33; 19.87; 21.85; 22.05; 23.32; 23.56; 23.92; 24.75; 25.55; 25.80; 27.05; 27.91; 30.25 ± 0.2 °.

Jaunās sāls struktūra ir apstiprināta ar monokristāla rentgenstruktūranalīzi. Kristāli ir monoklīni, šūnas parametri eksperimenta temperatūrā T = - 85 °C ir šādi: a= 13,2154(6) A, b= 7,5092(3) A, c= 17,6451(9) Α, β= 104,728(2)°, šūnas tilpums V = 1693,5(1) A3, telpiskā grupa P2]/a. 4-trimetilamoniobutanoāta acetilsalicilāta kristāla struktūras fragments:The structure of the new salt is confirmed by single crystal X-ray structure analysis. The crystals are monocular, the cell parameters at the experimental temperature T = - 85 ° C are as follows: a = 13.2154 (6) A, b = 7.5092 (3) A, c = 17.6451 (9) Α, β = 104.728 (2) °, cell volume V = 1693.5 (1) A 3 , space group P2] / a. Crystal fragment of 4-trimethylammoniobutanoate acetylsalicylate:

C6C6

2. piemērs. Z-kamitīna acetilsalicilskābes aditīvais sālsExample 2: Addition salt of Z-carnitine acetylsalicylic acid

Z-Kamitīnu (1,61 g, 10 mmol) un acetilsalicilskābi (1,80 g, 10 mmol) izšķīdina etanolā (20 ml) un šķīdumu koncentrē vakuumā pie aptuveni 40 °C līdz sīrupa konsistencei, kas atdziestot kristalizējas. Kristālisko masu saberž ar acetonu (50 ml), nofiltrē, noskalo ar acetonu un žāvē vakuumā istabas temperatūrā. Bezkrāsainu kristālu ar k.t. 90-94 °C iznākums ir 3,17 g (93%). Viela ir ūdenī šķīstoša, stabila parastos apstākļos.Z-Camitine (1.61 g, 10 mmol) and acetylsalicylic acid (1.80 g, 10 mmol) are dissolved in ethanol (20 mL) and the solution is concentrated in vacuo at about 40 ° C until the syrup is crystallized upon cooling. The crystalline mass is triturated with acetone (50 mL), filtered, rinsed with acetone and vacuum dried at room temperature. Colorless crystals with k.t. 90-94 ° C. Yield: 3.17 g (93%). The substance is water soluble, stable under normal conditions.

’H-KMR spektrs (CDC13, 200 MHz, δ): 2,32 (3H, s, COCH3); 2,53 (2H, d, J = 6,6 Hz, CH2COOH; 3,18 (9H, s, Me3N); 3,38-3,45 (2H, m, CH2N); 4,59 (1H, kvint, J = 6,1 Hz, CHOH); 7,15 (1H, dd, J = 1,1 un 8,1 Hz, H-3); 7,37 (1H, ddd, J = 1,1; 7,6 un 7,6 Hz, H-5); 7,56 (1H, ddd, J = 1,8; 7,8 un 7,8 Hz, H-4); 7,79 m.d. (1H, dd, J = 1,8 un 7,8 Hz, H-6).1 H-NMR Spectrum (CDCl 3 , 200 MHz, δ): 2.32 (3H, s, COCH 3 ); 2.53 (2H, d, J = 6.6 Hz, CH 2 COOH; 3.18 (9H, s, Me 3 N); 3.38-3.45 (2H, m, CH 2 N); , 59 (1H, quint, J = 6.1 Hz, CHOH); 7.15 (1H, dd, J = 1.1 and 8.1 Hz, H-3); 7.37 (1H, ddd, J = 1.1; 7.6 and 7.6 Hz, H-5); 7.56 (1H, ddd, J = 1.8; 7.8 and 7.8 Hz, H-4); 7.79 md (1H, dd, J = 1.8 and 7.8 Hz, H-6).

0ι6Η23ΝΟ7. Aprēķināts, %: C 56,30; H 6,79; N 4,10.0ι 6 Η 23 ΝΟ 7 . Calculated,%: C, 56.30; H, 6.79; N, 4.10.

Atrasts: %: C 55,67; H 6,85; N 4,12.Found:%: C 55.67; H, 6.85; N, 4.12.

Jauno sāli raksturo pulvera rentgenogramma (Cu Ka- radiācija) ar maksimumiem pie šādām 2Θ vērtībām: 5,09; 12,62; 13,48; 13,84; 15,04; 17,82; 19,15; 19,77; 21,84; 22,56; 23,33; 24,40; 23,92; 25,17; 25,43; 26,14; 27,24; 29,50; 30,36 ± 0,2°.The new salt is characterized by a powder radiograph (Cu K a - radiation) with peaks at the following 2Θ values: 5.09; 12.62; 13.48; 13.84; 15.04; 17.82; 19.15; 19.77; 21.84; 22.56; 23.33; 24.40; 23.92; 25.17; 25.43; 26.14; 27.24; 29.50; 30.36 ± 0.2 °.

Jaunās sāls struktūra ir apstiprināta ar monokristāla rentgenstruktūranalīzi. Kristāli ir monoklīni, šūnas parametri eksperimenta temperatūrā T = - 85 °C ir šādi: a= 13,1342(6) A, b = 7,6396(3) A, c = 17,737(1) Α, β = 104,535(2)°, šūnas tilpumsThe structure of the new salt is confirmed by single crystal X-ray structure analysis. The crystals are monocular, the cell parameters at the experimental temperature T = - 85 ° C are as follows: a = 13.1342 (6) A, b = 7.6396 (3) A, c = 17.737 (1) Α, β = 104.535 (2 ) °, cell volume

V - 1722,8(2) A3, telpiskā grupa P2j. £-kamitma acetilsalicilata kristālā struktūras fragments:V - 1722.8 (2) A 3 , P2j. Crystalline structure fragment of £ -chammax acetylsalicylate:

C5a C6aC5a C6a

3. piemērs. 3-ftrimetiIamonioamino)propanoāta acetilsalicilskābes adifivais sālsExample 3: Addition salt of 3-trimethylammonioamino) propanoate with acetylsalicylic acid

3-(Trimetilarnonioamino)propanoāta dihidrātu (SNN - Meldonium) (3,64 g, 20 mmol) un acetilsalicilicskābi (3,60 g, 20 mmol) maisot izšķīdina karstā propanolā2 (30 ml) un silda 20 minūtes pie aptuveni 50-55 °C. Sildīšanu pārtrauc un šķīdumu maisa istabas temperatūrā 3 stundas. Masu maisa pie 0 °C vēl 3 stundas, nogulsnes nofiltrē un noskalo ar aukstu propanolu-2 (2x15 ml). Iegūto produktu pārkristalizē no propanola-2. Bezkrāsainu kristālu ar k.t. 104-106 °C iznākums 4,12 g (63%).3- (Trimethylarnonioamino) propanoate dihydrate (SNN - Meldonium) (3.64 g, 20 mmol) and acetylsalicylic acid (3.60 g, 20 mmol) are dissolved in hot propanol2 (30 mL) and heated for 20 minutes at about 50-55 ° C. Stop heating and stir the solution at room temperature for 3 hours. The mass is stirred at 0 ° C for a further 3 hours, the precipitate is filtered off and rinsed with cold propanol-2 (2 x 15 mL). The product obtained is recrystallized from propanol-2. Colorless crystals with k.t. 104-106 ° C, 4.12 g (63%).

’H-KMR spektrs (CDC13, 200 MHz, δ): 2,34 (3H, s, COCH3); 2,51 (2H, t, J =1 H-NMR Spectrum (CDCl 3 , 200 MHz, δ): 2.34 (3H, s, COCH 3); 2.51 (2H, t, J =

6,4 Hz, CH2COO’); 3,26 (2H, t, J = 6,4 Hz, CH2N); 3,33 (9H, s, Me3N); 7,17 (1H, dd, J = 1,1 un 7,8 Hz, H-3); 7,39 (1H, ddd, J = 1,1; 7,6 un 7,6 Hz, H-5); 7,58 (1H, ddd, J = 1,7; 7,6 un 7,8 Hz, H-4); 7,81 m.d. (1H, dd, J = 1,7 un 7,6 Hz, H-6).6.4 Hz, CH 2 COO '); 3.26 (2H, t, J = 6.4 Hz, CH 2 N); 3.33 (9H, s, Me 3 N); 7.17 (1H, dd, J = 1.1 and 7.8 Hz, H-3); 7.39 (1H, ddd, J = 1.1; 7.6 and 7.6 Hz, H-5); 7.58 (1H, ddd, J = 1.7; 7.6 and 7.8 Hz, H-4); 7.81 md (1H, dd, J = 1.7 and 7.6 Hz, H-6).

Ci5H22N2O6. Aprēķināts, %: C 55,21; H 6,79; N 8,58.Ci 5 H 2 2 N 2 O 6. Calculated,%: C 55.21; H, 6.79; N, 8.58.

Atrasts, %: C 55,25; H 6,79; N 8,53.Found,%: C 55.25; H, 6.79; N, 8.53.

Jauno sāli raksturo pulvera rentgenogramma (Cu Ka- radiācija) ar maksimumiem pie šādām 2Θ vērtībām: 5,19; 13,22; 13,82; 14,20; 14,95; 15,36; 15,93; 18,11; 18,97; 19,74; 21,02; 22,15; 23,15; 23,65; 24,31; 25,28; 26,18; 26,58; 27,73; 28,36 ± 0,2°.The new salt is characterized by a powder radiograph (Cu K a - radiation) with peaks at the following 2Θ values: 5.19; 13.22; 13.82; 14.20; 14.95; 15.36; 15.93; 18.11; 18.97; 19.74; 21.02; 22.15; 23.15; 23.65; 24.31; 25.28; 26.18; 26.58; 27.73; 28.36 ± 0.2 °.

Jaunās sāls struktūra ir apstiprināta/pierādīta ar monokristāla rentgenstruktūranalīzi. Kristāli ir monoklīni, šūnas parametri eksperimenta temperatūrā T = - 85 °C ir šādi: a = 19,3399(8) A, b = 7,2400(3) A, c = 35,237(2) A, β = 90,758(2)°, šūnas tilpums V = 4933,5(4) A3, telpiskā grupa P2j/n. 3-(trimetilamonioamino)propanoāta acetilsalicilāta kristāla struktūras fragments:The structure of the new salt has been confirmed / proven by single crystal X-ray structure analysis. The crystals are monocular, and the cell parameters at the experimental temperature T = - 85 ° C are as follows: a = 19.3399 (8) A, b = 7.2400 (3) A, c = 35.237 (2) A, β = 90.758 (2) ) °, cell volume V = 4933.5 (4) A 3 , space group P2j / n. Crystal fragment of 3- (trimethylammonioamino) propanoate acetylsalicylate:

C15cC15c

C11cC11c

C10cC10c

Monokristālu rentgenstruktūranalīzes metode viennozīmīgi pierāda, ka kristāliskajā stāvoklī 3,3,3-trimetilamoniobutānskābes, L-kamitīna un 3-(trimetilamonioamino)propānskābes karboksilgrupas ir protonētas, kas nozīmē protona pārnesi no acetilsalicilskābes un sāls veidošanos. Karboksilgrupas C = O un C - 0 aditīvajam šālim ar acetilsaiicilskābi kristāliskajā struktūrā, 1,194 A un 1,308 A Lkamitīna aditīvajam šālim ar acetilsaiicilskābi kristāliskajā struktūrā un 1,219 A un 1,321 A 3-(trimetilamonio-amino)propānskābes aditīvajam šālim ar acetilsaiicilskābi kristāliskajā struktūrā. Savukārt visās tris struktūrās acetilsalicilskābes karboksilgrupas C=O un C-0 saites ir izlīdzinātas un tām ir vērtības ap 1,26 A.The X-ray monocrystalline analysis method unambiguously demonstrates that in the crystalline state the carboxyl groups of 3,3,3-trimethylammoniobutanoic acid, L-carnitine and 3- (trimethylammonioamino) propanoic acid are protonated, which means proton transfer from acetylsalicylic acid and salt formation. C = O and C - 0 carboxylic acid addition salts with acetylsalicylic acid in the crystalline structure, 1,194 A and 1,308 A Lkamitin addition salts with acetylsalicylic acid in the crystalline structure and 1,219 A and 1,321 A 3- (trimethylammonioamino) propanoic acid in the crystalline structure. In all three structures, however, the C = O and C-0 bonds of the acetylsalicylic acid carboxyl group are aligned and have values around 1.26 A.

4. piemērs. Antagonisms nikotīnskābes izraisītai ādas vazodilatācijaiExample 4. Antagonism of nicotinic acid vasodilatation of the skin

Modelis. Wistar žurku tēviņus narkotizē ar pentobarbitāla nātrija sāli (50 mg/kg i.p.) un narkozi uztur ar papildu devām (10 mg/kg) ik pēc stundas. Asinsspiedienu mēra kreisajā miega artērijā, EKG reģistrē ar standarta II novadījumu. Asins plūsmu labās auss artērijā mēra ar lāzera Doplera plūsmas mērītāju (OXYFLOW2000, USA). Asins plūsmu, EKG un arteriālo spiedienu reģistrē ar AD Instruments PmverLab sistēmām un saglabā datorā tālākai apstrādei. Pēc 10 min. ilgas bāzes līnijas reģistrācijas pētāmās vielas injicē s.c. skausta rajonā un turpina reģistrāciju vēl 30 min. Vidējos asins plūsmas datus katram dzīvniekam aprēķina, ņemot vērā vidējo asinsspiedienu, un salīdzina ar izejas stāvokli un kontroli. Rezultātus aprēķina no 5 - 8 atsevišķiem eksperimentiem un izteic kā maksimālās asins plūsmas izmaiņas % pret bāzlīniju [Carballo-Jane E et al, JPharmacol Toxicol Methods 2007;56(3):308-316].Model. Wistar male rats are anesthetized with pentobarbital sodium (50 mg / kg i.p.) and anesthetized with additional doses (10 mg / kg) every hour. Blood pressure is measured in the left carotid artery, ECG recorded with standard lead II. Blood flow in the right ear artery is measured with a laser Doppler flow meter (OXYFLOW2000, USA). Blood flow, ECG and arterial pressure are recorded with AD Instruments PmverLab systems and stored on a computer for further processing. After 10 min. long baseline registration test substances are injected s.c. in the withers and continues the registration for another 30 minutes. Mean blood flow data for each animal are calculated from mean blood pressure and compared with baseline and control. Results are calculated from 5 to 8 separate experiments and expressed as% change in maximal blood flow relative to baseline [Carballo-Jane E et al, JPharmacol Toxicol Methods 2007; 56 (3): 308-316].

Statistika. Rezultātus aprēķina kā vidējos ± SEM katrai grupai. Grupas robežās statistiskā analīze tika veikta ar Stjūdenta t-Testu. Atšķirības starp eksperimenta grupām salīdzina, izmantojot vienvirziena ANOVA ar atkārtotu salīdzināšanu (Tukey tests). P <0,05 tiek uzskatīts par nozīmīgu.Statistics. Results are calculated as mean ± SEM for each group. Within the group, statistical analysis was performed by Student's t-test. Differences between experimental groups are compared using one-way ANOVA with repeated comparison (Tukey's test). P <0.05 is considered significant.

RezultātiResults

Nikotīnskābe (NS) devā 15 mg/kg šajā dzīvnieka modelī izsauca nozīmīgu asins plūsmas pieaugumu auss artērijā (1. tabula). 3-(Trimetilamonioamino)propanoāta acetilsalicilskābes aditīvais sāls (TAP-AS), līdzīgi kontrolei (buferētam 0,9% NaCl šķīdumam), izsauca nenozīmīgas izmaiņas asins plūsmā. NS kopā ar TAPAS izsauca novēlotu (lēni pieaugošu) un statistiski nozīmīgi mazāk izteiktu absolūto asins plūsmas pieaugumu, salīdzinot ar NS vienu pašu (1. tabula). TAP-AS spējai antagonizēt nikotīnskābes izsauktu perifero vazodilataciju var but labvēlīgs efekts klīnikā, lai samazinātu nikotīnskābes nevēlamos efektus (ādas sasarkumu u.t.t.).Nicotinic acid (NS) at a dose of 15 mg / kg in this animal model caused a significant increase in blood flow to the ear artery (Table 1). 3- (Trimethylammonioamino) propanoate acetylsalicylic acid addition salt (TAP-AS), similar to control (buffered 0.9% NaCl solution), caused insignificant changes in blood flow. NS together with TAPAS induced a delayed (slowly increasing) and statistically significantly less pronounced absolute increase in blood flow compared to NS alone (Table 1). The ability of TAP-AS to antagonize nicotinic acid-induced peripheral vasodilatation may have a beneficial effect in the clinic in reducing the adverse effects of nicotinic acid (reddening of the skin, etc.).

Pētāmo vielu ietekme uz adas vazodilataciju, vidējais ± SEM. N=5-8 Effect of test substances on skin vasodilation, mean ± SEM. N = 5-8 Grupa Group Asins plūsmas izmaiņas. % Changes in blood flow. % Kontrole Control 2,92±2,76 2.92 ± 2.76 NS (15 mg/kg) NS (15 mg / kg) 55,75±11,5** 55.75 ± 11.5 ** TAP-AS (45 mg/kg) TAP-AS (45 mg / kg) 8,04±2.02i 8.04 ± 2.02 i NA + TAP-AS (15 + 45 mg/kg) NA + TAP-AS (15 + 45 mg / kg) 25,91±9,52*J 25.91 ± 9.52 * J

*F<(J,05 pret kontroli **P<0,005 pret kontroli $P<0,05 pretNS* F <{J, 05 versus control ** P <0.005 versus control $ P <0.05 versus control

SecinājumiConclusions

Mēs negaidīti atradām, ka acetilsalicilskābe veido kristāliskus, stabilus un ūdenī šķīstošus sāļus ar dažiem specifiskiem betaīniem, kam var būt plašāka pielietošana nekā acetilsalicil skābei vai betaīniem atsevišķi.We have unexpectedly found that acetylsalicylic acid forms crystalline, stable and water-soluble salts with some specific betaines, which may have broader applications than acetylsalicylic acid or betaines alone.

Claims (7)

PRETENZIJAS 1. 4-Trimetilamoniobutānskābes acetilsalicilskābes aditīvais sāls.Acetylsalicylic acid addition salt of 4-trimethylammoniobutanoic acid. 2. 4-Trimetilamoniobutānskābes acetilsalicilskābes aditīvais sāls saskaņā ar 1. pretenziju, kam raksturīga rentgenogramma ar maksimumiem pie 2Θ vērtībām 5,10; 13,58; 13,83; 15,02; 15,17; 17,89; 19,33; 19,87; 21,85; 22,05; 23,32; 23,56; 23,92; 24,75; 25,55; 25,80; 27,05; 27,91; 30,25 ± 0,2°.The acetylsalicylic acid addition salt of 4-trimethylammoniobutanoic acid according to claim 1, characterized by a radiograph with peaks at 2Θ values of 5.10; 13.58; 13.83; 15.02; 15.17; 17.89; 19.33; 19.87; 21.85; 22.05; 23.32; 23.56; 23.92; 24.75; 25.55; 25.80; 27.05; 27.91; 30.25 ± 0.2 °. 3. T-Karnitīna acetilsalicilskābes aditīvais sāls.3. T-Carnitine acetylsalicylic acid addition salt. 4. Τ-Karnitīna acetilsalicilskābes aditīvais sāls saskaņā ar 3. pretenziju, kam raksturīga rentgenogramma ar maksimumiem pie 2Θ vērtībām 5,09; 12,62; 13,48; 13,84; 15,04; 17,82; 19,15; 19,77; 21,84; 22,56; 23,33; 23,92; 24,40; 25,17; 25,43; 26,14; 27,24; 29,50; 30,36 ±0,2°.Α-Carnitine acetylsalicylic acid addition salt according to claim 3, characterized by a radiograph with peaks at 2Θ values of 5.09; 12.62; 13.48; 13.84; 15.04; 17.82; 19.15; 19.77; 21.84; 22.56; 23.33; 23.92; 24.40; 25.17; 25.43; 26.14; 27.24; 29.50; 30.36 ± 0.2 °. 5. 3-(Trimetilamonioamino)propānskābes (meldonija) acetilsalicilskābes aditīvais sāls.5. Addition salt of 3- (trimethylammonioamino) propanoic acid (meldonium) acetylsalicylic acid. 6. 3-(Trimetilamonioamino)propānskābes aditīvais sāls saskaņā ar 5. pretenziju, kam maksimumiem pie 2Θ vērtībām 5,19; 13,22; 13,82; 14,20; 14,95; 15,36; 15,93; 18,11; 18,97; 19,74; 21,02; 22,15; 23,15; 23,65; 24,31; 25,28; 26,18; 26,58; 27,73; 28,36 ± 0,2°.3- (Trimethylammonioamino) propanoic acid addition salt according to claim 5, having maxima at 2Θ values of 5.19; 13.22; 13.82; 14.20; 14.95; 15.36; 15.93; 18.11; 18.97; 19.74; 21.02; 22.15; 23.15; 23.65; 24.31; 25.28; 26.18; 26.58; 27.73; 28.36 ± 0.2 °. (meldonija) acetilsalicilskābes raksturīga rentgenogramma ar(Meldonium) acetylsalicylic acid characteristic radiograph with 7. 3-(Trimetilamonioamino)propānskābes acetilsalicilskābes aditīvais sāls pielietojumam nikotīnskābes izraisītas periferās vazodilatācijas (ādas apsārtuma) samazināšanai.7. The use of an acetylsalicylic acid addition salt of 3- (Trimethylammonioamino) propanoic acid for the reduction of nicotinic acid-induced peripheral vasodilation (redness of the skin).
LVP-09-117A 2009-06-25 2009-06-25 Novel salts of acetylsalicylic acid LV14273B (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
LVP-09-117A LV14273B (en) 2009-06-25 2009-06-25 Novel salts of acetylsalicylic acid
JP2012517421A JP5706409B2 (en) 2009-06-25 2010-06-21 New salicylate
PCT/LV2010/000007 WO2010151095A1 (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
NZ597510A NZ597510A (en) 2009-06-25 2010-06-21 NOVEL ACETYLSALICYLIC ACID SALTS, the salts are 4-trimethylammoniobutanoate, L-carnitine and meldonium
EP10735094.4A EP2445861B1 (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
US13/377,926 US8889902B2 (en) 2009-06-25 2010-06-21 Acetylsalicylic acid salts
UAA201200601A UA106379C2 (en) 2009-06-25 2010-06-21 Meldonium acetylsalicylic acid addition salts and use thereof as a medicinal agent
KR1020127001929A KR20120050437A (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
BRPI1009600A BRPI1009600A2 (en) 2009-06-25 2010-06-21
EA201200038A EA021588B1 (en) 2009-06-25 2010-06-21 Betain salts of acetylsalicylic acid
CA2766048A CA2766048A1 (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
CN201080028833.9A CN102803199B (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
GEAP201012546A GEP20146015B (en) 2009-06-25 2010-06-21 Novel acetylsalicylic acid salts
IL217036A IL217036A (en) 2009-06-25 2011-12-15 Acetylsalicylic acid addition salt, uses thereof in the preparation of medicaments, pharmaceutical compositions comprising the same and a combination medicinal product comprising such acid addition salt
ZA2012/00592A ZA201200592B (en) 2009-06-25 2012-01-24 Novel acetylsalicyclic acid salts
HK12110406.3A HK1169648A1 (en) 2009-06-25 2012-10-19 Novel acetylsalicylic acid salts

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-09-117A LV14273B (en) 2009-06-25 2009-06-25 Novel salts of acetylsalicylic acid

Publications (2)

Publication Number Publication Date
LV14273A LV14273A (en) 2011-01-20
LV14273B true LV14273B (en) 2011-06-20

Family

ID=52681821

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-09-117A LV14273B (en) 2009-06-25 2009-06-25 Novel salts of acetylsalicylic acid

Country Status (2)

Country Link
LV (1) LV14273B (en)
UA (1) UA106379C2 (en)

Also Published As

Publication number Publication date
UA106379C2 (en) 2014-08-26
LV14273A (en) 2011-01-20

Similar Documents

Publication Publication Date Title
ES2456142T3 (en) Chemical compositions and methods for making them
DE69632193T2 (en) CYCLOOXYGENASEINHIBITOR AND SALTS OF AMIDINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS DRUGS AND MEDICAMENTS CONTAINING SUCH SALTS
JP2015510010A5 (en)
BRPI1015120B8 (en) Alpha-substituted lipid compound, derivatives of polyunsaturated beta-oxo fatty acids, pharmaceutical and lipid composition and methods for producing lipid compound and 2-((5z,8z,11z,14z,17z)-icosa-5,8, 11,14,17-pentaenyloxy)butanoic
CN106511110B (en) Application and its synthetic method of the dihydro oat alkaloid D salt compounds as cosmetic active ingredient
PT1667960E (en) Meldonium salts, method of their preparation and pharmaceutical composition on their basis
US7687650B2 (en) Chemical compositions and methods of making them
EP1368303B1 (en) Halogen-substituted amino dicarboxylic acid derivatives as medicaments for treating cardiovascular diseases
JP5134530B2 (en) Boswellic acid and novel salt of selectively concentrated boswellic acid and method therefor
WO2019044773A1 (en) Functional skin preparation for external use, antimicrobial agent and method for producing aromatic polyhydroxycarboxylic acid or derivative thereof
JPWO2014027669A1 (en) Pyrroloquinoline quinone tetraalkali salt and crystal thereof, production method thereof, and composition
WO2012070649A1 (en) Highly-soluble pyrroloquinoline quinone salt and method for producing same
US4089954A (en) Metal salts of fatty acid derivatives of amino acids
JP6073929B2 (en) Germanium complex with amino acid and carboxylic acid, and preparation method thereof
WO2012118532A1 (en) A tri amino releasing fulvate
JP2023085312A (en) Thiamine compound, preparation method and pharmaceutical composition thereof
LV14273B (en) Novel salts of acetylsalicylic acid
JPH0420427B2 (en)
FI3989741T3 (en) Particulate composition containing co-crystal of malic acid and alkali metal hydrogen malate
EP3558920B1 (en) Improved synthesis of lysine acetylsalicylate · glycine particles
JPWO2020040017A1 (en) Methods for producing pharmaceuticals, anticancer agents, pharmaceutical intermediates and cyclic carboxylic acid compounds or derivatives thereof
US4372954A (en) Moroxydine phenoxyisobutyrates and method of use
CA2832693C (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium salts in the treatment of cardiovascular disease
US7956218B2 (en) Organic salts of β-alanine
EP2848608B1 (en) Silver complex compounds, method for their production and their use